| | |
1-YEAR SURVIVAL
|
2-YEARS SURVIVAL
|
5-YEARS SURVIVAL
|
|---|
|
Covariate
| |
Hazard ratio (95% CI)*
|
P Value
|
Hazard ratio (95% CI)*
|
P Value
|
Hazard ratio (95% CI)*
|
P Value
|
|---|
|
Gender
|
(male vs. females)
|
1.00 (0.61-1.63)
|
0.99
|
1.08 (0.75-1.57)
|
0.66
|
1.00 (0.75-1.35)
|
0.98
|
|
Age
|
(per 10 years)
|
1.00 (0.98-1.02)
|
0.69
|
0.99 (0.98-1.00)
|
0.19
|
1.00 (0.99-1.01)
|
0.83
|
|
Duration of Disease
|
(per year)
|
0.94 (0.86-1.04)
|
0.22
|
0.93 (0.86-0.99)
|
0.03
|
0.97 (0.93-1.01)
|
0.16
|
|
Previous Surgery
|
(vs. no surgery)
|
0.59 (0.33-1.04)
|
0.07
|
0.57 (0.38-0.87)
|
0.009
|
0.63 (0.45-0.87)
|
0.006
|
|
Previous Chemotherapy
|
(vs. no chemotherapy)
|
1.28 (0.75-2.19)
|
0.37
|
1.28 (0.86-1.93)
|
0.23
|
1.68 (1.21-2.32)
|
0.002
|
|
Previous Radiation
|
(vs. no radiation)
|
0.63 (0.31-1.31)
|
0.22
|
0.75 (0.45-1.25)
|
0.27
|
0.93 (0.62-1.39)
|
0.72
|
|
Solitary Metastases
|
(vs. multiple metastases)
|
0.38 (0.11-1.37)
|
0.14
|
0.60 (0.22-1.60)
|
0.31
|
0.63 (0.29-1.38)
|
0.25
|
|
Liver Metastases
|
(vs. no liver metastases)
|
1.83 (0.68-4.95)
|
0.24
|
1.40 (0.68-2.92)
|
0.36
|
1.57 (0.88-2.80)
|
0.13
|
|
Bone Metastases
|
(v. no bone metastases)
|
1.59 (0.90-2.81)
|
0.11
|
1.18 (0.74-1.87)
|
0.49
|
1.38 (0.94-2.01)
|
0.10
|
|
Tumor Uptake Score 2
|
(vs. uptake score 1)
|
1.47 (0.35-6.14)
|
0.60
|
2.10 (0.69-6.42)
|
0.19
|
0.77 (0.31-1.92)
|
0.58
|
|
Tumor Uptake Score 3
|
(vs. uptake score 1)
|
0.51 (0.13-2.09)
|
0.35
|
0.85 (0.28-2.61)
|
0.78
|
0.40 (0.16-0.98)
|
0.05
|
|
Low Dose [90Y-DOTA]-TOC
|
(vs. High Dose)
|
0.93 (0.19-4.58)
|
0.93
|
0.39 (0.13-1.19)
|
0.10
|
0.39 (0.16-0.96)
|
0.04
|
|
Intermediate Dose [90Y-DOTA]-TOC
|
(vs. High Dose)
|
0.74 (0.24-2.31)
|
0.61
|
0.52 (0.25-1.11)
|
0.09
|
0.57 (0.33-0.99)
|
0.05
|
- *Estimates for each co-variable have been adjusted for histology as a categorical co-variable, for the cumulative [90Y-DOTA]-TOC activity as well as for all other co-variables listed.
